Paediatric patching not necessary

Article

Early unilateral cataract surgery in infants can produce good visual outcomes even if patching is discontinued, according to a study in the August 2008 issue of the Archives of Ophthalmology.

Early unilateral cataract surgery in infants can produce good visual outcomes even if patching is discontinued, according to a study in the August 2008 issue of the Archives of Ophthalmology.

Scott R. Lambert, MD of Emory Eye Center, Atlanta, US and colleagues conducted a medical record review of paediatric subjects (n=9) who had undergone surgery to treat unilateral congenital cataract at a mean age of 21.7 days. Subjects had remained patched for a mean 6.7 hours/day until at least 12 months of age, after which patching compliance declined to a mean of 1.7 hours/day by six years of age.

Four children abandoned patching entirely before their sixth birthdays: three maintained or increased visual acuity, whereas the fourth child lost two lines.

The researchers concluded that, if patients comply with the prescribed patching regime in early childhood, visual acuity can be maintained if patching is discontinued before the patient reaches six years of age.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.